Search





Search





Markets
/
Stocks
/
nasdaq-acet
/

Adicet Bio Inc

ACET

Add to Watchlist

7.680USD

-0.730-8.68%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

71.79MMarket Cap

LossP/E TTM



Adicet Bio Inc

7.680

-0.730-8.68%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Adicet Bio Inc

Currency: USD Updated: 2026-05-15

Key Insights

Adicet Bio Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 84 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 34.83.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Adicet Bio Inc's Score

Industry at a Glance

Industry Ranking

84 / 382

Overall Ranking

202 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Adicet Bio Inc Highlights

StrengthsRisks

Adicet Bio, Inc. is a clinical-stage biotechnology company. It is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases. ADI-001 contains an anti-CD20 CAR that has a proprietary antigen-binding domain that recognizes a region of CD20 distinct from that recognized by rituximab. Its pipeline also includes ADI-270, an investigational allogeneic gamma delta CAR T cell therapy targeting CD70 via the CD27-ligand for the treatment of RCC and with potential in other solid tumor and hematological malignancy indications. Its pipeline has additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.

Fairly Valued

The company’s latest PE is -0.55, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 7.16M shares, increasing 22.43% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 242.94K shares of this stock.

Analyst Rating

Based on 6 analysts

Strong Buy

Current Rating

34.833

Target Price

+314.19%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-15

The current financial score of Adicet Bio Inc is 6.43, ranking 242 out of 382 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

6.43

Change



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.41

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

8.93

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Adicet Bio Inc's Company Valuation

Currency: USD Updated: 2026-05-15

The current valuation score of Adicet Bio Inc is 7.10, ranking 164 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.55, which is -42.29% below the recent high of -0.32 and -1164.41% above the recent low of -7.00.

Score

Industry at a Glance

Previous score

7.10

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 84/382

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-15

The current earnings forecast score of Adicet Bio Inc is 8.86, ranking 44 out of 382 in the Biotechnology & Medical Research industry. The average price target is 8.00, with a high of 9.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

9.00

Change

-0.14

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 6 analysts

Strong Buy

Current Rating

34.833

Target Price

+314.19%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Adicet Bio Inc

ACET

CRISPR Therapeutics AG

CRSP

Beigene Ltd

ONC

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-15

The current price momentum score of Adicet Bio Inc is 7.10, ranking 101 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 8.62 and the support level at 7.01, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.23

Change

-2.13

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.130

Neutral

RSI(14)

46.972

Neutral

STOCH(KDJ)(9,3,3)

31.243

Sell

ATR(14)

0.547

High Vlolatility

CCI(14)

-59.505

Neutral

Williams %R

75.776

Sell

TRIX(12,20)

0.507

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

8.056

Sell

MA10

8.266

Sell

MA20

8.124

Sell

MA50

7.462

Buy

MA100

7.605

Buy

MA200

7.216

Buy

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Adicet Bio Inc is 7.00, ranking 83 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 75.97%, representing a quarter-over-quarter increase of 66.85%. The largest institutional shareholder is James Simons, holding a total of 232.59K shares, representing 2.49% of shares outstanding, with 153.84% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

RA Capital Management, LP

948.25K

+101.19%

OrbiMed Advisors, LLC

1.03M

-0.00%

Franklin Advisers, Inc.

626.57K

Woodline Partners LP

625.00K

Adage Capital Management, L.P.

274.38K

Two Sigma Investments, LP

256.13K

+146.75%

Prosight Capital

250.24K

Renaissance Technologies LLC

Star Investors

242.94K

+112.53%

Goldman Sachs & Company, Inc.

234.51K

+0.01%

Risk Assessment

Currency: USD Updated: 2026-05-15

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Adicet Bio Inc is 1.29, ranking 315 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 1.52. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.